World’s first study of digital follow-up of patients treated with immune-checkpoint inhibitors uses Kaiku Health.

Real-World Data published based on Kaiku Health Immune Checkpoint Inhibitor Module in collaboration with Oulu University Hospital and Docrates Cancer Center. This study is the first of its kind in the world investigating complementary digital interventions in the follow-up of cancer patients receiving immune checkpoint inhibitor therapies in a real world setting. The Kaiku Health algorithms were able to detect symptoms of differing severities, allowing intervention at an earlier stage. Interestingly correlations were also found between certain adverse events and possible clinical benefits. Kaiku Health is a Debiopharm Innovation Fund portfolio company.

The full press release is available on Kaiku Health’s website